Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Leronlimab is glorified saline and probably easier to make
How much does each 700mg dose of leronlimab cost to manufacture? Is it $40? Or is that the price of a vial? How big of a vial? (cue the tikitiki post highlighting my subpar stats recollection)
They are making 100000 treatments so 500 divided by 3 doses is 175 per vial or so,
They need 300,000 vials to treat 100000 patients
100 thousand
How much does it cost to manufacture one vial of lenz?
https://ir.humanigen.com/news/news-details/2021/Humanigen-Reports-First-Quarter-2021-Financial-Results/default.aspx
The company plans to submit an EUA application at the end of May 2021. The company has also been in discussion with the Medicines and Healthcare Products Regulatory Agency (“MHRA”) for the use of lenzilumab in COVID-19 patients in the United Kingdom and plans to initiate a rolling CMA submission before the end of the second quarter of 2021. The company also plans to submit for CMA to the European Medicines Agency (“EMA”) for the use of lenzilumab in the European Union.
Nice Post!
Your DD is for the birds. You should probably sell on Monday if you really think the trials are going into 2021. FDA is going to approve Leronlimab in July. Count on it.
He mentioned EU in the video. Top line report going to EU for approval too.
More likely EUA is coming.
“My prediction is no buyout but multiple licensing agreements with 2-3 BPs.”
My gut says the same. I’d accept a BO of $50 + shares, or higher. However, I believe partnerships are far more likely.
It’s almost harder to believe talks are *not* happening.
He promised “top line” this week. The rest of the data will come. JFC, people are so impatient.
Nader isn't a colossal failure, Leronlimab is. The drug is garbage
To be fair, CytoDyn didn't really have the option to go with a more reputable lender than Fife. Fife charges an exorbitant amount to high risk customers. He is the equivalent of the credit card that charges 28% to people with poor credit. He is Pay Day Loans.
If the stock rises, Fife goes unnoticed. If the stock falls, it'll seem like he individually tanked the stock.
Is there some sort of PROBLEM to call the University to confirm? Waiting...
Yup, his Ph.D. from the University of Utah in 1998 has not been confirmed via official graduating class roster.
https://www.mech.utah.edu/pourhassan/
Still, Pourhassen, who was born in Iran and who has a PhD in mechanical engineering from the University of Utah, exudes confidence about CytoDyn’s future.
His PhD from UOU has not been confirmed.
In the 2 minutes of 2:33pm EST and 2:34pm EST, approximately 350,000 shares were sold. It actually had little effect on the stock price.
Nader Pourhassan and John Fife both attended Brigham Young University in 1985 and 1986. I wonder if they knew each other? For anyone interested in John Fife:
Fife has operated as what’s called a “toxic lender” for many years. Microcap companies trading on the over-the-counter market typically have limited access to traditional financing. Desperate for cash, they sign on with financiers like Fife who purchase securities—usually convertible promissory notes or convertible debentures—from them. The financiers charge extremely high interest, but that’s the least of their clients’ problems. Upon conversion, the lenders enjoy a discount to market price that may be as high as 60 percent, and higher in the event of default by the issuer. As he converts portions of his note and sells the resulting stock into the market in a series of tranches, the stock’s price plummets. That is why these kinds of instruments are called “death spiral convertibles.” Eventually, the dilution caused by the conversions may force the issuer to reverse split the company’s stock. Sometimes it drives the company into bankruptcy.
https://www.securitieslawyer101.com/2020/sec-says-toxic-funder-john-m-fife-is-an-unregistered-dealer/
Nevertheless, after today's rousting... an update on progress would help....
Oh my I'm so impressed!!!
Looky here:
Time........ Price.... Volume
16:02:06 $2.5341 195,055
16:02:06 $2.5341 250,000
CYDY down 9.89%. Too bad it wasn't 10% to prevent shorting tomorrow. Closing one cent lower would have been enough. So if you bought at $2.45 at 3:59pm, you are the reason.
In our case, Nasdaq going down is probably more like a cover for short-sellers to slam down the price in coordination with uncertain or lack of good news. We are not in Nasdaq yet, so no big ETF type investment would have us included that our price will fall along with XBI etc. That's my logic.
Who do you think is primarily causing the price to go down this week (after the Philippines video)?
And what are the spectacular earth shattering results derived from PRO 140 being used for cancer that came after CytoDyn bought it?
Please include links.
an Oncology company? Good question. Progenics, the folks that sold the failed molecule PRO 140 to Cytodyn is an oncology company but dropped PRO140/leronlimab---
As we have expanded our focus on oncology, we have terminated certain research efforts not within the Company’s oncology focus, and are working to out-license others, such as our PRO 140 and C.difficile programs.
Investors have seemingly fallen smitten with anything that leaves Nader’s mouth yet comfortable with the fact he’s has NEVER delivered! There’s always a new “hope”, a new “deal” to be working on.
Thank you for an English class , I always appreciate.
I see that SOME know nothing about Leronlimab treatment but are VERY vocal.
600 applications held up since 2014 ? Looks like those will benefit from anti red tape long before we do In Philippines
Perhaps the older more severe cases were enrolled later in the trial.
Obviously it couldn't be used to justify an EUA yet because 28-day endpoints failed
The increased dosing theory requires a new trial of course
It seems pretty obvious that CYDY is headed down to the $2.40-$2.60 range. It likes that range a lot. One piece of slightly bad news will send it tumbling to $2.00.
I think 82% in 14 days is probably true, that would be a pretty egregious lie.
You know how sometimes a household is having extreme financial problems but the parents don't let their children know? This is you. Nader is the father and he isn't letting you know how dire the financial situation is. But when the family has to move out of their house and into a homeless shelter, it isn't possible to keep it a secret from the children any longer. That time is coming. Without real revenue real soon, the CytoDyn family is going to be living in the homeless shelter.
Nader spoke over the weekend and so far we are down 15% since Friday.
"You're looking at short volume, not short interest. " -- No. I'm looking at short interest from I-broker (which obviously is just 1 broker but gives a decent glimpse into the market)
The results after 14 days appears to be good after doses at day 0 and day 7. Therefore in a short term review that is what the DSMC saw.